LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Improved Myeloma Diagnosis Based on Blood Count Components

By LabMedica International staff writers
Posted on 27 Aug 2018
Image: A photomicrograph of a myeloma colored with hematoxylin and eosin stain (Photo courtesy of Wikipedia Commons).
Image: A photomicrograph of a myeloma colored with hematoxylin and eosin stain (Photo courtesy of Wikipedia Commons).
A team of British researchers has found which blood tests could be useful for suggesting or excluding a diagnosis of myeloma.

Multiple myeloma is a hematological cancer characterized by numerous non-specific symptoms leading to diagnostic delay in a large proportion of patients. Symptoms can occur up to two years before diagnosis in other cancers, but little is known about the timing of symptoms and abnormal blood test results before diagnosis in myeloma.

Investigators at the University of Exeter (United Kingdom) and the University of Oxford (United Kingdom) sought to identify the best inflammatory markers for initial investigation of possible myeloma, useful blood tests for ruling out symptomatic myeloma, and how to distinguish early and late features of the disease.

For this study, they analyzed symptom prevalence and blood tests up to five years before diagnosis in 2703 cases and 12,157 matched controls. Likelihood ratios (LR) were used to classify tests or their combinations as useful rule-in or rule-out tests.

Results suggested that the best inflammatory markers to supplement symptoms of myeloma were plasma viscosity (PV) and erythrocyte sedimentation rate (ESR), while C-reactive protein (CRP) was unhelpful. In addition, the combination of normal hemoglobin and PV could be used to rule out the disease on patients currently being tested in primary care. The results further demonstrated that the full blood count components and especially low hemoglobin were among the earliest presentations of the disease, which may allow the diagnosis to be expedited.

Senior author Dr. William Hamilton, professor of primary care diagnostics at the University of Exeter, said, "Ordinarily a GP will see a patient with myeloma every five years - and early diagnosis matters. More timely treatment could significantly improve survival rates for this disease. We report a simple way a GP can check patients presenting symptoms such as back, rib, and chest pain, or recurrent chest infections, and determine whether they have myeloma or not."

The study was published in the August 13, 2018, online edition of the British Journal of General Practice.

Related Links:
University of Exeter
University of Oxford

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Human Estradiol Assay
Human Estradiol CLIA Kit

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more